50% OFF
MarketBeat All Access
Get 30 days free. Save 50% your first year.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
S&P 500   3,655.04
DOW   29,260.81
QQQ   274.37
This Device Makes Creating Voice Memos Easy
Goldman Sachs Alum Sounds Alarm on "Next US Crisis" (Ad)
Three Consumer Stocks That Could Outperform In Q4 
Will Synthetic Biology Firm Amyris Post Net Income In 2024?
Goldman Sachs Alum Sounds Alarm on "Next US Crisis" (Ad)
Comcast is an Asset Bonanza Priced Cheap
US stocks slip deeper into a slump as recession fears grow
Goldman Sachs Alum Sounds Alarm on "Next US Crisis" (Ad)
British pound plunges to new low as tax cuts spark concern
Lights out, ovens off: Europe preps for winter energy crisis
S&P 500   3,655.04
DOW   29,260.81
QQQ   274.37
This Device Makes Creating Voice Memos Easy
Goldman Sachs Alum Sounds Alarm on "Next US Crisis" (Ad)
Three Consumer Stocks That Could Outperform In Q4 
Will Synthetic Biology Firm Amyris Post Net Income In 2024?
Goldman Sachs Alum Sounds Alarm on "Next US Crisis" (Ad)
Comcast is an Asset Bonanza Priced Cheap
US stocks slip deeper into a slump as recession fears grow
Goldman Sachs Alum Sounds Alarm on "Next US Crisis" (Ad)
British pound plunges to new low as tax cuts spark concern
Lights out, ovens off: Europe preps for winter energy crisis
S&P 500   3,655.04
DOW   29,260.81
QQQ   274.37
This Device Makes Creating Voice Memos Easy
Goldman Sachs Alum Sounds Alarm on "Next US Crisis" (Ad)
Three Consumer Stocks That Could Outperform In Q4 
Will Synthetic Biology Firm Amyris Post Net Income In 2024?
Goldman Sachs Alum Sounds Alarm on "Next US Crisis" (Ad)
Comcast is an Asset Bonanza Priced Cheap
US stocks slip deeper into a slump as recession fears grow
Goldman Sachs Alum Sounds Alarm on "Next US Crisis" (Ad)
British pound plunges to new low as tax cuts spark concern
Lights out, ovens off: Europe preps for winter energy crisis
S&P 500   3,655.04
DOW   29,260.81
QQQ   274.37
This Device Makes Creating Voice Memos Easy
Goldman Sachs Alum Sounds Alarm on "Next US Crisis" (Ad)
Three Consumer Stocks That Could Outperform In Q4 
Will Synthetic Biology Firm Amyris Post Net Income In 2024?
Goldman Sachs Alum Sounds Alarm on "Next US Crisis" (Ad)
Comcast is an Asset Bonanza Priced Cheap
US stocks slip deeper into a slump as recession fears grow
Goldman Sachs Alum Sounds Alarm on "Next US Crisis" (Ad)
British pound plunges to new low as tax cuts spark concern
Lights out, ovens off: Europe preps for winter energy crisis
NASDAQ:SAVA

Cassava Sciences - SAVA Stock Reddit Activity & Social Media Sentiment

$45.19
+3.32 (+7.93%)
(As of 09/26/2022 12:00 AM ET)
Add
Compare
Today's Range
$40.75
$47.67
50-Day Range
$16.33
$51.06
52-Week Range
$13.84
$100.00
Volume
7.56 million shs
Average Volume
2.29 million shs
Market Capitalization
$1.81 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$44.00

Reddit Posts Over Time



View Trending Reddit Stocks

WallStreetBets Posts Over Time



View Trending WallStreetBets Stocks

Media Mentions Over Time



View Trending Media Stocks

MarketBeat New Follows Over Time



View Trending Stocks on MarketBeat

MarketBeat Searches Over Time



Recieve SAVA News and Ratings via Email

Sign-up to receive the latest news and ratings for Cassava Sciences and its competitors with MarketBeat's FREE daily newsletter.


SAVA Social Media Mentions

Recent SAVA Stock Reddit Threads

September 22nd, 2022  5:37 PM  |  volumeticker |  StockMarket
volume leaders at the close - 09.22.22

Another wild day! Cassava Sciences, Inc. traded 744% above average volume, $SAVA closed up 35.65% Cano Health, Inc. traded 488% above average volume, $CANO closed up 32.17% Change Healthcare Inc. traded 433% above average volume, $CHNG closed up 0.22% Virtu …

September 22nd, 2022  4:50 PM  |  Hopes-Dreams-Reality |  WallStreetbetsELITE
$SAVA anyone? Up 35% to $51...👍🏼🚀 or 👎🏼💩

Poppin or Floppin?

September 20th, 2022  3:50 PM  |  Phx-Jay |  wallstreetbets
Cassava Sciences (SAVA) - The Real Moon 🚀

So much negative info has been said of SAVA. They have been accused of fraud. They have been accused of doctoring results. Lawsuits have been filed, petitions to the FDA, articles written, and so on and so on….all by people shorting the stock. This isn’t mo own …

September 11th, 2022  3:40 PM  |  Nebula_Which |  wallstreetbets
$SAVA is the way

Disclaimer : I have $23k in SAVA and this is not Financial Advice However SAVA ‘s drug is going to be a life changing drug for Alzheimer’s patients. It have proven to have no side effects and help improve cognition and symptoms of dementia. Currently has several analysts buy ratings …

August 24th, 2022  12:18 PM  |  Midnight9Nine |  wallstreetbets
SAVA Short Squeeze

Cassava Sciences, Inc. (SAVA) No Evidence of Data Manipulation in Science Publication on Simufilam as the short sellers made up the story to short it into the ground. Now the proof is out that it was made up, the short sellers have to cover Still 30% of float is short. …

August 22nd, 2022  10:31 PM  |  Some-nexx-guy |  wallstreetbets
Cassava or nah

I was checking out my yahoo watch list and came across SAVA and remembered this hot stock. Its a bio pharm company thats working on alzeimers drug A month ago it got hit with a potential DOJ probe into data and test result manipulation of some sort with its test studies and the …

August 18th, 2022  10:12 AM  |  Aedon1s |  wallstreetbets
$SAVA Short Squeeze update, saved me from going red on $BBBY

Posted about this the other day here. Saved me from going red on $BBBY. Their CEO and CTO bought mil. of shares last week. Some good news came out today: >Cassava Sciences Shares Soar on Journals Finding of No Data Manipulation in Simufilam Paper > >Cassava Sciences

August 17th, 2022  11:47 AM  |  Aedon1s |  wallstreetbets
$SAVA making more gains than $BBBY

Looked at this stock yesterday after doing some short squeeze research. Chart looks great and it fits all the requirements for a short squeeze. Couldnt get a position yesterday because my money was settling. Got in today though. Short Interest Increase: +12% Short Ratio (Days to …

August 17th, 2022  10:44 AM  |  RondoDuckFish |  wallstreetbets
SAVA is through the roof

as of august 17 at 10:44AM, SAVA is going like crazy and I recommend that you guys should check it out. It’s back on the climb now and 16.9M shares have been traded as of now

August 17th, 2022  10:30 AM  |  spaceman_spiff_0 |  wallstreetbetsOGs
Buy some $SAVA. Come back in 2 years. You’re welcome.

SAVA may have an effective treatment for Alzheimer’s. You’ve heard this before. A bunch of you will downvote this for reasons I don’t understand. Anyway…. There has been a lot of swirl around supposedly fabricated data. The data in question, even if it is bullshit, …

August 16th, 2022  4:58 PM  |  UncommonBird |  wallstreetbets
Insiders buying $SAVA

Insiders buying $SAVA ​

August 10th, 2022  4:45 AM  |  maxxou89 |  wallstreetbets
Buy $SAVA and get rich!

$SAVA is facing the biggest short and distort campaign in the history of the sotck market. Once their alzheimer drug is proven efficient (and it will), this is gonna be a 100 X. Plus you get to fuck crooks that tries to stop trials of a drug that could save millions of people …

August 8th, 2022  10:08 AM  |  Phx-Jay |  wallstreetbets
Cassava Sciences (SAVA) is the best gamble

I have some BBBY like everyone else but there are 80M shares with a little over 35% short this morning (per Schwab stats). I’m ready for it to moon. However, SAVA is the real moon. They only have 40M shares with about 25% short. They have now enrolled over 400 patients …

July 30th, 2022  5:33 PM  |  Timelycommentor |  wallstreetbets
Wallstreetbets disregard for $SAVA is laughable.

The short selling tactics of distort and short have been successful at their FUD campaign. It’s amusing watching everyone shill for Big Pharma (who is not your friend) simply because they do not own the methodology and research that is developing ground breaking AD treatment. Once …

July 27th, 2022  12:46 PM  |  MamothMamoth |  wallstreetbets
Bullish on $SAVA

If your following the $SAVA saga, by now your familiar with allegations of fraud. Just today the DOJ launched an investigation. Super bearish. Also the Journal Science just published a paper outlining how the past 20 years of research into Alzheimer is based on fabricated …

July 24th, 2022  8:10 PM  |  comfytoday |  wallstreetbets
Fabricated research and corruption behind $SAVA new Alzeimer drug: Aduhelm

I never post here, but I thought this was pretty relevant... In depth article, with original research: Hard to overstate the consequences of this fraud charge. tldr: Entire Alzeimers research field is embroiled in a massive charge of fraudulent research that goes …

July 5th, 2022  10:36 AM  |  makegains26 |  pennystocks
$RDHL top 10 undervalued biopharm in the market IMO.load up on bears markets and dump on bulls market or with news.these are the tickers that can make you rich.my original account is (sammy2607) NFA

Made millions on tickers like this and $SAVA was one of them.at the price now I believe downside is almost nothing amd upside potential is CRAZY.good luck on your trades

This page (NASDAQ:SAVA) was last updated on 9/27/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.